During the years 2000 to 2002, many reports appeared in the literature on protein profiling with SELDI-TOF
mass spectrometry (MS) for cancer diagnosis.
Finally, researchers are evaluating the potential of protein chip arrays and SELDI-TOF
mass spectrometry for identifying novel protein biomarkers that can be used as indicators of the onset and eventual progression of the cognitive decline associated with early AD.
Clinical proteomics: searching for better tumour markers with SELDI-TOF
Samples analyzed by SELDI-TOF
were thawed only once.
For example, Petricoin et al (2002a, 2002b) developed classification models for early detection of ovarian and prostate cancers (PCAs) on the basis of SELDI-TOF
MS data using a genetic algorithm-based SVM.
Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF
and their identification by combined liquid chromatography-tandem mass spectrometry.
MS approach to proteomics: protein profiling and biomarker identification.
Reproducibility of SELDI-TOF
protein patterns in serum: comparing datasets from different experiments.
Preanalytic influence of sample handling on SELDI-TOF
serum protein profiles.
Our test kitchen focused on SELDI-TOF
mass spectrometry, a technology with a throughput that allows the assessment of relatively large numbers (i.
Accordingly, we postulated SELDI-TOF
MS technology to be a more appropriate proteomic approach for detecting low molecular weight proteins (<20 kDa), because such an approach permits rapid analysis of hundreds of serum samples at a time (23).
We searched the serum proteome of astrocytoma patients and control subjects using SELDI-TOF
mass spectrometry (MS), which has successfully identified serum biomarkers in other forms of cancer (5, 6) and infection (7).